A ten-year hemovigilance report in the regional blood transfusion center of Sfax (Tunisia)

##plugins.themes.academic_pro.article.sidebar##

Published Feb 1, 2025
https://doi.org/10.62438/tunismed.v103i2.5445
Download
pdf
Vol. 103 No. 2 (2025): Tunis Med Feb 2025

##plugins.themes.academic_pro.article.main##

Taicir Rekik
Regional blood transfusion center of Sfax, Tunisia
Sana Cherif
Regional blood transfusion center of Sfax, Tunisia
Nour Louati
Regional blood transfusion center of Sfax, Tunisia
Ines Maaloul
Pediatric departement Hedi Chaker university hospital, Sfax,Tunisia
Jalel Gargouri
Regional blood transfusion center of Sfax, Tunisia
Héla Menif
Regional blood transfusion center of Sfax, Tunisia
Ikram Ben Amor
Regional blood transfusion center of Sfax, Tunisia

Abstract

Objectives: In Tunisia, despite hemovigilance regulations since 2007, transfusion adverse events (TAEs)


remain underreported. Here, we analyze and evaluate the reported TAEs over ten years in the


blood transfusion center of Sfax (Tunisia).


Methods: This is a ten-year (2012-2021) descriptive and exhaustive report on TAE from the second


largest blood center in Tunisia, where around 56,000 labile blood products are issued annually.


Results: Four-hundred-sixty-four TAEs were reported. The median age of the patients was 38 years (1


month to 94 years). The sex ratio was 0.68. The overall TAE annual incidence per issued labile


blood product was 0.77‰ and ranged from 0.47 to 1.43‰. The most common TAE was a


febrile non-hemolytic reaction (31.7%), followed by an allergic reaction (21.6%). The severity


degree was informed in 433 cases (93.3%). Grade 1 severity was the most common (80.8%),


followed by grades 3, 2 and 4 (10.6%, 1.3% and 0.6%, respectively). Packed red blood cells


were the most implicated labile blood product (81.5%). Standard platelet concentrates and fresh


frozen plasma accounted for 6.5% and 5% of the total adverse transfusion reactions,


respectively.


Conclusion: The TAE incidence in our study seems to be underestimated compared to worldwide reported TAEs.


The analysis of reported TAEs in our context illustrates the insufficiency of the regulation's


implementation alone.

Keywords:

hemovigilance, adverse transfusion reaction, declaration, transfusion safety

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Circulaire n°24/2007. Organisation de l'hémovigilance en Tunisie. Ministère de la santé Tunisienne. 2007. https://santetunisie.rns.tn/images/cir2015/cir472.pdf.
  2. Krishnamurthy AV, Mathialagan J, Raghavan ATMV, Srinivasan S. Analysis of Patterns of Adverse Transfusion Reactions and Management: A Novel Initiative toward Hemovigilance in a Teaching Hospital of South India. J Lab Physicians. 2020;12(2):133‑40.
  3. Sharma DK, Datta S, Gupta A. Study of acute transfusion reactions in a teaching hospital
  4. of Sikkim: A hemovigilance initiative. Indian J Pharmacol. 2015;47(4):370‑4.
  5. Pai S. Surveillance of Transfusion Related Adverse Reactions in a Tertiary Care Centre in
  6. Bangalore: A 4-Year Hemovigilance Initiative. Indian J Hematol Blood Transfus. 2020;36(4):733‑9.
  7. Bassi R, Aggarwal S, Bhardwaj K, Thakur KK. Patterns of Adverse Transfusion Reactions
  8. in a Tertiary Care Centre of North India: A Step Towards Hemovigilance. Indian J Hematol Blood Transfus. 2017;33(2):248‑53.
  9. Owusu-Ofori AK, Owusu-Ofori SP, Bates I. Detection of adverse events of transfusion in
  10. a teaching hospital in Ghana: Adverse events of transfusion in Ghana. Transfus Med. 2017;27(3):175‑80.
  11. Hatayama Y, Matsumoto S, Hamada E, Kojima N, Hara A, Hino N, et al. Analysis of Acute
  12. Transfusion Reactions and Their Occurrence Times. Yonago Acta Med. 2018;61(1):87‑90.
  13. Cho J, Choi SJ, Kim S, Alghamdi E, Kim HO. Frequency and pattern of noninfectious
  14. adverse transfusion reactions at a tertiary care hospital in Korea. Ann Lab Med. 2016;36(1):36‑41.
  15. Wahidiyat PA, Marpaung E, Iskandar SD. Characteristics of Acute Transfusion Reactions
  16. and its related factors in Cipto Mangunkusumo Hospital Jakarta, Indonesia. Health Sci J Indones. 2019;10(1):15‑20.
  17. Michlig C, Vu DH, Wasserfallen JB, Spahn DR, Schneider P, Tissot JD. Three years of
  18. haemovigilance in a general university hospital. Transfus Med. 2003;13(2):63‑72.
  19. Boudjedir K, Drougard S, Freyche C,Lenzotti AM, Sandid I. 20ème Rapport d'activité
  20. d’hémovigilance. Paris: Agence nationale de sécurité du médicament. 2023;1-211.
  21. https://ansm.sante.fr/uploads/2023/11/27/20231127-rapport-hemovigilance-2022.pdf
  22. Kracalik I, Mowla S, Basavaraju SV, Sapiano MRP. Transfusion‐related adverse reactions:
  23. Data from the national healthcare safety network hemovigilance module - united states, 2013–2018. Transfusion. 2021;61(5):1424‑34.
  24. Mahjoub S, Baccouche H, Raissi A, Ben Hamed L, Ben Romdhane N. Hémovigilance à
  25. Tunis (hôpital La Rabta) : bilan 2007–2013. Transfus Clin Biol. 2017;24(1):15‑22.
  26. Ouadghiri S, Brick C, Benseffaj N, Atouf O, Essakalli M. Effets indésirables receveurs à
  27. l’hôpital Ibn Sina de Rabat : bilan 1999–2013. Transfus Clin Biol. 2017;24(1):23‑7.
  28. Beckers EA, Dinkelaar RB, te Boekhorst PA, van Ingen HE, van Rhenen DJ. Reports of
  29. transfusion incidents: experiences from the first year of hemovigilance in the region of the former ZWN (South West Netherlands) blood bank in Rotterdam. Ned Tijdschr Geneeskd. 2003;147(31):1508‑12.
  30. Kar YD, Yildirgan DO, Aygun B, Erdogmus D, Altinkaynak K. Retrospective evaluation
  31. of acute transfusion reactions in a tertiary hospital in Erzurum, Turkey. North Clin Istanb. 2021;8(3):261‑8.
  32. Bisht A, Marwaha N, Kaur R, Gupta D, Chhabra R. Haemovigilance Programme of India:
  33. Comparative analysis of transfusion reactions reported over a 5-year period through two
  34. reporting formats and key recommendations for blood safety. Asian J Transfus Sci. 2020;14(2):103‑16.
  35. Xue T, Yujie K, Jue W, Rui H, Ling L, Zhong L. Development of the Chinese
  36. Haemovigilance Network and reporting of adverse transfusion reactions from 2018 to 2020. Vox Sang. 2022 Aug;117(8):1027-1034.
  37. Khalid S, Usman M, Khurshid M. Acute transfusion reactions encountered in patients at a
  38. tertiary care center. J Pak Med Assoc. 2010;60(10):832-6.
  39. Mafirakureva N, Khoza S, Mvere DA, Chitiyo ME, Postma MJ, van Hulst M. Incidence
  40. and pattern of 12 years of reported transfusion adverse events in Zimbabwe: a retrospective
  41. analysis. Blood Transfus. 2014;12(3):362‑7.
  42. Marwaha N, Roy P, Bhattacharya P, Dhawan H, Sharma R. Transfusion-related adverse
  43. events at the tertiary care center in North India: An institutional hemovigilance effort. Asian J Transfus Sci. 2011;5(2):164.
  44. Kumar P, Thapliyal R, Coshic P, Chatterjee K. Retrospective evaluation of adverse
  45. transfusion reactions following blood product transfusion from a tertiary care hospital: A
  46. preliminary step towards hemovigilance. Asian J Transfus Sci. 2013;7(2):109.
  47. Saha S, Krishna D, Prasath R, Sachan D. Incidence and Analysis of 7 Years Adverse
  48. Transfusion Reaction: A Retrospective Analysis. Indian J Hematol Blood Transfus. 2020;36(1):149‑55.
  49. Wang Y, Sun W, Wang X, Ren X, Gao A, Li M, et al. Comparison of transfusion reactions in children and adults: A systematic review and meta-analysis. Pediatr Blood Cancer. 2022 Sep;69(9): e29842.
  50. Moncharmont P. Adverse transfusion reactions in transfused children. Transfus Clin Biol. 2019;26(4):329‑35.
  51. Vossoughi S, Perez G, Whitaker BI, Fung MK, Stotler B. Analysis of pediatric adverse
  52. reactions to transfusions: adverse pediatric transfusion reactions. Transfusion. 2018;58(1):60‑9.
  53. Zhang X, Zhang Y, Qi C, Ma C. Analysis of Adverse Reactions of Blood Transfusion and Discussion of Influencing Factors in Linyi Area from 2013 To 2020. Iran J Public Health. 2021;50(7):1416‑20.
  54. Payandeh M, Zare ME, Kansestani AN, Pakdel SF, Jahanpour F, Yousefi H, et al. Descriptions of acute transfusion reactions in the teaching hospitals of kermanshah university of medical sciences, Iran. Int J Hematol-Oncol Stem Cell Res. 2013;7(2):11‑6.
  55. Borhany M, Anwar N, Tariq H, Fatima N, Arshad A, Naseer I, et al. Acute blood transfusion
  56. reactions in a tertiary care hospital in Pakistan ‐ an initiative towards haemovigilance. Transfus Med. 2019;29(4):275‑8.
  57. Linden JV, Wagner K, Voytovich AE, Sheehan J. Transfusion errors in New York State: an analysis of 10 years’ experience. Transfusion. 2000;40(10):1207‑13.
  58. Ben Gayed K, Hafyen A. Audit about the knowledge of healthcare personnel regarding transfusion: A multicenter study. Tunis Med. 2024;102(7): 415-18.
  59. Garraud O, Sut C, Haddad A, Tariket S, Aloui C, Laradi S, et al. Transfusion-associated hazards: A revisit of their presentation. Transfus Clin Biol J. 2018;25(2):118‑35.
  60. Narayan DS, Baker DP, Bellamy PM, Bentley DA, Bolton-Maggs DP, Booth DC, et al. The 2023 Annual SHOT Report, Manchester: Serious Hazards of Transfusion (SHOT) Steering Group. https://doi.org/10.57911/605r-em59.
  61. Goel R, Tobian AAR, Shaz BH. Noninfectious transfusion-associated adverse events and
  62. their mitigation strategies. Blood. 2019;133(17):1831‑9.
  63. Vossoughi S, Gorlin J, Kessler DA, Hillyer CD, Van Buren NL, Jimenez A, et al. Ten years of TRALI mitigation: measuring our progress. Transfusion. 2019;59(8):2567‑74.
  64. Roubinian N. TACO and TRALI: biology, risk factors, and prevention strategies. Hematology. 2018(1):585‑94.
  65. Sawadogo S, Nebie K, Millogo T, Sontie S, Nana A, Dahourou H, et al. Traceability of
  66. Blood Transfusions and Reporting of Adverse Reactions in Developing Countries: A Six-
  67. Year Postpilot Phase Experience in Burkina Faso. Adv Hematol. 2018:1‑9.